CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $327,638,000 | -20.2% | 64,369 | -0.7% | 0.00% | – |
| Q2 2021 | $410,495,000 | +79.4% | 64,849 | +119.1% | 0.00% | – |
| Q1 2021 | $228,769,000 | -29.3% | 29,595 | -40.1% | 0.00% | – |
| Q4 2020 | $323,381,000 | -1.5% | 49,371 | 0.0% | 0.00% | – |
| Q3 2020 | $328,318,000 | +27.4% | 49,371 | +59.6% | 0.00% | – |
| Q2 2020 | $257,656,000 | +22.5% | 30,931 | +12.8% | 0.00% | – |
| Q1 2020 | $210,296,000 | -26.8% | 27,418 | -20.7% | 0.00% | – |
| Q4 2019 | $287,385,000 | +5.1% | 34,583 | -6.7% | 0.00% | – |
| Q3 2019 | $273,459,000 | -14.7% | 37,054 | +29.7% | 0.00% | – |
| Q2 2019 | $320,489,000 | +21.2% | 28,564 | +16.2% | 0.00% | – |
| Q1 2019 | $264,343,000 | +34.7% | 24,590 | +89.2% | 0.00% | – |
| Q4 2018 | $196,300,000 | -18.4% | 13,000 | 0.0% | 0.00% | – |
| Q3 2018 | $240,500,000 | -13.1% | 13,000 | +7.4% | 0.00% | – |
| Q2 2018 | $276,606,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |